Investing.com - Biomerieux reported on Wednesday second quarter earnings that beat analysts' forecasts and revenue that fell short of expectations.
Biomerieux announced earnings per share of €2.33 on revenue of €729.6M. Analysts polled by Investing.com anticipated EPS of €2.09 on revenue of €774M.
Biomerieux shares are down 6% from the beginning of the year and are trading at €108.00 , down-from-52-week-high.They are under-performing the STOXX 600 which is up 18.57% from the start of the year.
Biomerieux follows other major Healthcare sector earnings this month
Biomerieux's report follows an earnings missed by EssilorLuxottica on Friday, August 20, 2021, who reported EPS of €1.93 on revenue of €4.71B, compared to forecasts EPS of €2.31 on revenue of €4.59B.
Valneva had matched expectations on Tuesday, August 10, 2021 with second quarter EPS of €-0.61 on revenue of €24.29M, compared to forecast for EPS of €-0.61 on revenue of €24.3M (NYSE:MMM).
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar